Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Skye BioscienceSKYE | Open-market sale | 09/22–09/23 | 09/24 | 148,079 sh4 trades | $1.62avg. | $239,555.19 | −100.0% | |
Skye BioscienceSKYE | Open-market sale | 09/22–09/23 | 09/24 | 148,079 sh4 trades | $1.62avg. | $239,555.19 | −100.0% | |
10% Owner | Skye BioscienceSKYE | Open-market sale | 09/22–09/23 | 09/24 | 148,079 sh4 trades | $1.62avg. | $239,555.19 | −100.0% |
Skye BioscienceSKYE | Open-market sale | 09/22–09/23 | 09/24 | 148,079 sh4 trades | $1.62avg. | $239,555.19 | −100.0% | |
Skye BioscienceSKYE | Open-market sale | 09/22–09/23 | 09/24 | 148,079 sh4 trades | $1.62avg. | $239,555.19 | −100.0% | |
Skye BioscienceSKYE | Open-market sale | 09/22–09/23 | 09/24 | 148,079 sh4 trades | $1.62avg. | $239,555.19 | −100.0% | |
Skye BioscienceSKYE | Open-market sale | 09/22–09/23 | 09/24 | 148,079 sh4 trades | $1.62avg. | $239,555.19 | −100.0% | |
10% Owner | Skye BioscienceSKYE | Open-market sale | 09/22–09/23 | 09/24 | 148,079 sh4 trades | $1.62avg. | $239,555.19 | −100.0% |
Skye BioscienceSKYE | Open-market sale | 09/22–09/23 | 09/24 | 148,079 sh4 trades | $1.62avg. | $239,555.19 | −100.0% | |
Skye BioscienceSKYE | Open-market sale | 25/08/21–25/08/22 | 25/08/22 | 231,405 sh4 trades | $3.46avg. | $800,548.5 | −80.1% | |
Skye BioscienceSKYE | Open-market sale | 25/08/21–25/08/22 | 25/08/22 | 231,405 sh4 trades | $3.46avg. | $800,548.5 | −80.1% | |
10% Owner | Skye BioscienceSKYE | Open-market sale | 25/08/21–25/08/22 | 25/08/22 | 231,405 sh4 trades | $3.46avg. | $800,548.5 | −80.1% |
Skye BioscienceSKYE | Open-market sale | 25/08/21–25/08/22 | 25/08/22 | 231,405 sh4 trades | $3.46avg. | $800,548.5 | −80.1% | |
Skye BioscienceSKYE | Open-market sale | 25/08/21–25/08/22 | 25/08/22 | 231,405 sh4 trades | $3.46avg. | $800,548.5 | −80.1% | |
Skye BioscienceSKYE | Open-market sale | 25/08/21–25/08/22 | 25/08/22 | 231,405 sh4 trades | $3.46avg. | $800,548.5 | −80.1% | |
Skye BioscienceSKYE | Open-market sale | 25/08/21–25/08/22 | 25/08/22 | 231,405 sh4 trades | $3.46avg. | $800,548.5 | −80.1% | |
10% Owner | Skye BioscienceSKYE | Open-market sale | 25/08/21–25/08/22 | 25/08/22 | 231,405 sh4 trades | $3.46avg. | $800,548.5 | −80.1% |
Skye BioscienceSKYE | Open-market sale | 25/08/21–25/08/22 | 25/08/22 | 231,405 sh4 trades | $3.46avg. | $800,548.5 | −80.1% | |
Skye BioscienceSKYE | Open-market saleAmendment | 24/11/15–24/11/18 | 25/02/28 | 43,216 sh2 trades | $4.99avg. | $215,754.24 | −20.5% | |
Skye BioscienceSKYE | Open-market sale | 24/11/15–24/11/18 | 24/11/20 | 19,574 sh2 trades | $4.99avg. | $97,721.86 | −19.2% |
